ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

In Brief: Ethics Commission To Consider Staff Proposal For Compensation Program At Future Meeting

March 13, 1981

2015 Goal Not a Dream, But a Vision, Director Says

July 18, 2003

FDA Approves Xeloda For Breast Cancer After Failure Of Anthracycline Treatment.

September 28, 2001

LeMaistre Blasts “Death Merchants’ In tobacco Industry

May 5, 1989

Market Forces Changing Health Care System, Oncologists Told

June 2, 1995

NSABP “Saddened” But Some Patient Advocates Hail “Courageous” Decision.

June 22, 2007